Followers | 831 |
Posts | 120032 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
Sunday, September 30, 2007 10:46:55 PM
They won’t. But they may spend almost that much on the global Tyzeka program.
Under the old arrangement, IDIX paid half of certain Tyzeka expenses related to commercialization in the US and Western Europe. Since IDIX says it will save $40-45M per year from the restructuring, it might seem that NVS will now spend $80-90M per year plus whatever it costs to commercialize the drug in Asia and other regions not covered by the original agreement.
However, NVS will actually spend less than the above amount for several reasons:
1. The overhead of running the joint venture has been eliminated.
2. For a given number of sales reps, it is less costly for NVS to sell than for IDIX to sell because NVS has other drugs for its reps to detail.
3. NVS may intend to reduce the number of total details for Tyzeka, although this hasn’t yet been acknowledged by either company.
For IDIX investors, only item #3 remains relevant.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM